{"schema_version":"secwatch.filing_event.v1","accession":"0001999371-25-013413","form_type":"8-K","ticker":"TNXP","cik":"0001430306","company_name":"Tonix Pharmaceuticals Holding Corp.","filed_at":"2025-09-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.976083+00:00","generated_at":"2026-05-17T06:20:52.678106+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Tonix in-licenses Phase 2/3-ready Lyme disease antibody TNX-4800","bullets":["In-licensed worldwide rights to TNX-4800, a fully human monoclonal antibody targeting OspA of Borrelia burgdorferi.","Designed as a single subcutaneous dose each Spring to protect against Lyme disease through Fall tick season.","Positive Phase 1 study showed safety, tolerability, and linear PK/PD/efficacy relationship (1:1:1).","Planning adaptive Phase 2/3 study; ~70 million people in U.S. endemic areas eligible for treatment.","Developed by UMass Chan Medical School; no FDA-approved vaccines currently available for Lyme disease."],"urls":{"canonical":"https://secwatch.observer/filing/0001999371-25-013413","json":"https://secwatch.observer/filing/0001999371-25-013413.json","markdown":"https://secwatch.observer/filing/0001999371-25-013413.md","text":"https://secwatch.observer/filing/0001999371-25-013413.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1430306/000199937125013413/0001999371-25-013413-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1430306/000199937125013413/tnxp-8k_091725.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T06:20:52.678106+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}